Form: SC 13G

Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions

August 21, 2023

Documents

 

EXHIBIT 99.1

 

JOINT FILING AGREEMENT

 

The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Shares of Benitec Biopharma Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the undersigned.

 

This Agreement may be executed in counterparts and each of such counterparts taken together shall constitute one and the same instrument.

 

Dated August 21, 2023.

 

 

CITADEL SECURITIES LLC   CITADEL ADVISORS LLC
         
By: /s/ Guy Miller   By: /s/ Noah Goldberg
  Guy Miller, Authorized Signatory     Noah Goldberg, Authorized Signatory
         
         
CITADEL SECURITIES GROUP LP   CITADEL ADVISORS HOLDINGS LP
         
By: /s/ Guy Miller   By: /s/ Noah Goldberg
  Guy Miller, Authorized Signatory     Noah Goldberg, Authorized Signatory
         
         
CITADEL SECURITIES GP LLC   CITADEL GP LLC
         
By: /s/ Guy Miller   By: /s/ Noah Goldberg
  Guy Miller, Authorized Signatory     Noah Goldberg, Authorized Signatory
         
         
      KENNETH GRIFFIN
         
      By: /s/ Noah Goldberg
        Noah Goldberg, attorney-in-fact*

 

 

* Noah Goldberg is signing on behalf of Kenneth Griffin as attorney-in-fact pursuant to a power of attorney previously filed with the Securities and Exchange Commission, and hereby incorporated by reference herein. The power of attorney was filed as an attachment to a filing by Citadel Advisors LLC on Schedule 13G for Zentalis Pharmaceuticals Inc. on April 9, 2020.